R

Respiri Ltd
ASX:RSH

Watchlist Manager
Respiri Ltd
ASX:RSH
Watchlist
Price: 0.08 AUD Market Closed
Market Cap: 103.3m AUD
Have any thoughts about
Respiri Ltd?
Write Note

Respiri Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Respiri Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
R
Respiri Ltd
ASX:RSH
Cash & Cash Equivalents
AU$762.9k
CAGR 3-Years
-54%
CAGR 5-Years
20%
CAGR 10-Years
-21%
ImpediMed Ltd
ASX:IPD
Cash & Cash Equivalents
AU$24.6m
CAGR 3-Years
8%
CAGR 5-Years
17%
CAGR 10-Years
9%
C
Cyclopharm Ltd
ASX:CYC
Cash & Cash Equivalents
AU$27.6m
CAGR 3-Years
-5%
CAGR 5-Years
37%
CAGR 10-Years
35%
Cochlear Ltd
ASX:COH
Cash & Cash Equivalents
AU$513.6m
CAGR 3-Years
-6%
CAGR 5-Years
46%
CAGR 10-Years
25%
Optiscan Imaging Ltd
ASX:OIL
Cash & Cash Equivalents
AU$6.1m
CAGR 3-Years
-10%
CAGR 5-Years
28%
CAGR 10-Years
56%
EMvision Medical Devices Ltd
ASX:EMV
Cash & Cash Equivalents
AU$18.6m
CAGR 3-Years
24%
CAGR 5-Years
34%
CAGR 10-Years
N/A
No Stocks Found

Respiri Ltd
Glance View

Market Cap
103.3m AUD
Industry
Health Care

Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-07-14. The firm's segments include Australia and Israel. The Australia segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Israel. The firm has developed a wheezo, which is an eHealth Saas platform that uses a device and app to measure, record and assist asthma monitoring. Its device and app make up a cloud-based mobile health platform that records wheeze and other clinically relevant symptoms and signs of asthma.

RSH Intrinsic Value
0.01 AUD
Overvaluation 90%
Intrinsic Value
Price
R

See Also

What is Respiri Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
762.9k AUD

Based on the financial report for Jun 30, 2024, Respiri Ltd's Cash & Cash Equivalents amounts to 762.9k AUD.

What is Respiri Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-21%

Over the last year, the Cash & Cash Equivalents growth was 422%. The average annual Cash & Cash Equivalents growth rates for Respiri Ltd have been -54% over the past three years , 20% over the past five years , and -21% over the past ten years .

Back to Top